ShK-186: Phase Ib started

Kineta began a 2-part, U.S. Phase Ib trial of ShK-186. In the initial dose-escalation part, healthy volunteers will receive 1 of 4 doses of ShK-186 in a 28-day cycle until the maximum tolerated dose (...